I-SPY 2 predicts veliparib success, sets faster cancer drug path
This article was originally published in Scrip
Executive Summary
AbbVie's veliparib has a 92% chance of success in a Phase III clinical trial for hard-to-treat triple-negative breast cancer versus the standard of care, according to the multi-arm, investigator-sponsored I-SPY 2 clinical trial, which is designed to identify novel cancer agents that could be more rapidly developed and approved.